Background. Mycobacterium ulcerans is the causative agent of a debilitating skin and soft tissue 25 infection known as Buruli ulcer (BU). There is no vaccine against BU. The purpose of this study 26 was to investigate the vaccine potential of two previously described immunogenic M. 27 ulcerans proteins, MUL_3720 and Hsp18, using a mouse tail infection model of BU. 28 Methods. Recombinant versions of the two proteins were each electrostatically coupled with a 29 previously described lipopeptide adjuvant. Seven C57BL/6 and seven BALB/c mice were 30 vaccinated and boosted with each of the formulations. Vaccinated mice were then challenged 31 with M. ulcerans via subcutaneous tail inoculation. Vaccine performance was assessed by time-32 to-ulceration compared to unvaccinated mice. 33 Results. The MUL_3720 and Hsp18 vaccines induced high titres of antigen-specific antibodies 34 that were predominately subtype IgG 1 . However, all mice developed ulcers by day-40 post-M. 35 ulcerans challenge. No significant difference was observed in the time-to-onset of ulceration 36 between the experimental vaccine groups and unvaccinated animals.
Introduction
Western Blotting 141 Proteins were separated on a 12% polyacrylamide gel as per the method for SDS-PAGE. After 142 separation proteins were transferred to a nitrocellulose membrane in tris-glycine transfer buffer 143 (1.5 mM Tris, 12mM glycine, 15 % methanol (v/v) in distilled water) for 1 hour at 100 volts 144 (Mini Trans-Blot Cell, Bio-Rad). The nitrocellulose membrane was blocked in blocking buffer 145 (5% (w/v) skim milk powder and 0.1% Tween-20 in PBS) overnight at 4°C. The membrane was 146 8 incubated in blocking buffer containing anti-6xHIS-HRP antibody (Roche Applied Science) at 147 1:500 dilution. The membrane was washed in PBS containing 0.1% Tween-20 and then exposed 148 to developing solution (Western Lighting Chemiluminescence kit, Perkin Elmer) according to 149 manufacturer's guidelines. Chemiluminescence was detected using an MF ChemiBIS gel 150 imaging system (DNR Bio-Imaging Systems). animals used for scientific purposes). All protocols were approved by the Ethics Committee of 170 region Pays de la Loire under protocol nos. CEEA 2009.14 and CEEA 2012.145 . Animals were 171 maintained under specific pathogen-free conditions in the animal house facility of the Centre 172 Hospitalier Universitaire, Angers, France (agreement A 49 007 002). Six-week old female 173 C57BL/6 and BALB/c mice were obtained from Charles River Laboratories Nuelles, France) and housed at CHU Angers. Food and water were given ad libitum. The synthesis and purification of the branched cationic lipopeptide, R 4 Pam 2 Cys, was performed 179 as previously described [45, 50, 51] . Each vaccine dose contained 25 µg protein formulated in 180 PBS with R 4 Pam 2 Cys at a 1:5 molar ratio of protein to lipopeptide in a final volume of 100 µl.
181
The protein alone control formulation contained 25 ug protein per dose diluted in PBS. The Serum was prepared from blood obtained from mice at day 0, day 18, day 33 and day 63.
205
Antibody titres were measured using enzyme linked immunosorbent assay (ELISA) as per 206 methods described in [45] . Briefly, ELISA plates (Nunc, Thermo Scientific) were coated 207 overnight with 5 µg protein diluted in PBSN 3 and blocked with BSA 10 PBS for 2 hours at room 208 temperature. Plates were washed with PBS containing 0.05% Tween-20 (PBST). Neat sera were 209 sequentially diluted in BSA 5 PBST and incubated at room temperature for 6 hours. Bound 210 antibody was detected by adding horse radish peroxidase conjugated rabbit anti-mouse IgG 211 (Dako, Glostrup, Denmark) at a concentration of 1:400 in BSA 5 PBST for 2 hours. Plates were 212 developed with developing solution (hydrogen peroxide, citric acid and ABTS) and incubated for (Table S1 ). Purification of the 236 recombinant proteins was confirmed by SDS-PAGE and Western blot analyses of the eluate (Fig.   237 1). DLS analysis was then performed to identify whether recombinant MUL_3720 or Hsp18 238 would electrostatically bind to either the positively charged lipopeptide adjuvant R 4 Pam 2 Cys, or 239 its negatively charged counterpart, E 8 Pam 2 Cys. The optical density of solutions containing these 240 constituents at a wavelength of 450nm (OD 450 ) is related to the particle size of molecules in 241 solution, reflecting the strength of the ionic interaction between protein and lipopeptide [45] .
242
MUL_3720 preferentially bound to R 4 Pam 2 Cys compared to E 8 Pam 2 Cys ( Fig. 2A) . This is 243 shown as a gradual increase in optical density following the addition of increasing amounts of 244 R 4 Pam 2 Cys to a constant amount of MUL_3720. At a 5-fold molar excess of protein to 245 lipopeptide the OD 450 plateaued, suggesting MUL_3720 bound most strongly to R 4 Pam 2 Cys at a 246 1:5 protein to lipopeptide ratio. Conversely, when E 8 Pam 2 Cys was added to MUL_3720 the 247 optical density remained static and did not increase with increasing lipopeptide concentrations, 248 indicating a lack of binding. Hsp18 also appeared to bind preferentially to R 4 Pam 2 Cys and also at 249 a 1:5 ratio of Hsp18 to R 4 Pam 2 Cys ( Figure 2B ). Therefore, two protein-adjuvant formulations 250 were prepared using MUL_3720 with R 4 Pam 2 Cys and Hsp18 with R 4 Pam 2 Cys, both at a 1:5 251 protein to lipopeptide molar ratio. Vaccination with MUL_3720 recombinant protein alone or MUL_3720 + R 4 Pam 2 Cys were 261 capable of inducing MUL_3720-specific antibody titres in both BALB/c and C57BL/6 strains of 262 13 mice ( Fig. 3A, B ). Primary vaccination with MUL_3720 protein alone induced MUL_3720-263 specific antibody responses that significantly increased (p < 0.0001) following a vaccine boost (p 264 = 0.0234). Additionally, MUL_3720 + R 4 Pam 2 Cys generated MUL_3720 specific antibody 265 responses after primary vaccination (p < 0.0001 in BALB/c and C57BL/6), which were increased 266 after the secondary boost (p < 0.0001 in BALB/c and not statistically significant in C57BL/6).
267
The titres after the boost in particular were greater than MUL_3720 alone vaccination (p = 268 0.0031 in BABL/c and p = 0.006 in C57BL/6). Mice that were not vaccinated with recombinant 269 MUL_3720 (R 4 Pam 2 Cys alone and BCG) did not have an increase in MUL_3720-specific 270 antibodies compared to naïve mice. induced Hsp18-specific antibody responses in both mouse strains after primary vaccination (p < 278 0.0001 in BALB/c and p = 0.0165 in C57BL/6) and the Hsp18-specific antibody titre 279 significantly increased after booster vaccination (p < 0.0001 in BALB/c and p = 0.0016 in 280 C57BL/6). In all strains, the antibody titres induced by Hsp18 + R 4 Pam 2 Cys were significantly 281 higher than vaccination with Hsp18 protein alone (p = 0.0004 in BALB/c and p < 0.0001 in Quantifying levels of IgG antibody shows that the predominant isotypes produced by 288 MUL_3720 were IgG 1 and IgG2 b (Fig. 3E ) with no significant difference between these isotype 289 titres. Vaccination with MUL_3720 + R 4 Pam 2 Cys produces significantly more IgG 1 and IgG2 b 290 antibodies (p = 0.0076). The antibody titres for both isotypes were highest prior to infection with 291 M. ulcerans (day 33) and decreased after infection by day 63. This vaccine was capable of 292 inducing IgG2a antibodies, which was detected also on day 33, however in smaller amounts than 293 IgG 1 and IgG2 b (p = 0.0399 for MUL_3720 + R 4 Pam 2 Cys) ( Fig. 3E ).
295
Similar to vaccination with MUL_3720, Hsp18 was also capable of inducing strong IgG 296 antibody titres. The predominant isotype was IgG 1 which Hsp18 + R 4 Pam 2 Cys elicited more than 297 any other isotype ( Fig. 3F) including IgG2 a and IgG2 b , Again, these titres was highest at day 33 298 and decreased significantly after infection on day 63. This trend was also observed after 299 vaccination with Hsp18 alone (p = 0.0018 vs IgG2 a and p = 0.0076 vs IgG2 b , respectively at day 300 33). (Table 1 and Table 2 ) and all mice reached ulceration by day 63, 30 days post-M. ulcerans 319 challenge (Fig. 5A, B) . antibodies against the recombinant protein with which they were vaccinated ( Figure 3A-3D) . In 328 BALB/c mice (Fig. 3A, C) the antibody titres at day 63 were lower than after the secondary 329 response prior to challenge (p < 0.0001 for both Hsp18 + R 4 Pam 2 Cys and MUL_3720 + 330 16 R 4 Pam 2 Cys) but remained significantly higher than at day 0 (p < 0.0001 for both Hsp18 + 331 R 4 Pam 2 Cys and MUL_3720 + R 4 Pam 2 Cys). In C57BL/6 mice ( Fig. 3B and 3D) , antibody titres 332 against MUL_3720 or Hsp18 from mice vaccinated with either protein alone or protein plus 333 lipopeptide adjuvant were also significantly decreased at day 63 compared to the secondary 334 response at day 35 (p < 0.0001 and p = 0.0406 for MUL_3720 + R 4 Pam 2 Cys and Hsp18 + 335 R 4 Pam 2 Cys, respectively). Similar to BALB/c mice, the day 63 respective protein-specific 336 antibodies for MUL_3720 + R 4 Pam 2 Cys and Hsp18 + R 4 Pam 2 Cys were significantly higher than 337 at day 0 (p < 0.0001 and p = 0.0004 for MUL_3720 + R 4 Pam 2 Cys and Hsp18 + R 4 Pam 2 Cys, 338 respectively). responses are much lower than the protein-specific antibody responses generated from 347 MUL_3720 or Hsp18 vaccinated mice, particularly in C57/BL6 mice (p < 0.0001) (Fig. 6 ).
348
Animals from both mouse strains that were vaccinated with R 4 Pam 2 Cys alone or BCG showed 349 no increase in protein-specific antibody responses against either recombinant MUL_3720 and This study aimed to develop a vaccine against M. ulcerans utilizing two previously described 355 cell-wall associated proteins, Hsp18 and MUL_3720 [40] [41] [42] [43] . Both the MUL_3720 and Hsp18-356 based vaccines were capable of inducing high antibody titres, but these responses were not 357 associated with protection ( Fig. 5 ). This may indicate that these proteins, while strongly In this study, all mice succumbed to infection in a relatively short period (40 days) compared to 412 previous mouse tail infection models [70] and human BU, where the incubation period is 413 estimated at 4.8 months before the onset of ulceration [71] . All BALB/c and C57BL/6 mice 414 succumbed to infection by 40 days after MU infection, even mice that were vaccinated by M. 415 bovis BCG. M. bovis BCG has been previously shown to delay the onset of disease on average 416 by at least 6 weeks [21, 22, 31] . In this study however, there was no significant difference 417 between mice vaccinated with either MUL_3720 or Hsp18 protein alone or with both proteins 418 plus R 4 Pam 2 Cys. This suggests that M. bovis BCG is ineffective at protecting mice in this model environmental sources of M. ulcerans [9, [72] [73] [74] [75] , consistent with the hypothesis that a relatively 423 small bacterial inoculum is required to establish BU [9] . At the time this study was conducted the 424 minimum infectious dose (ID 50 ) for BU had not been determined, however the ID 50 has since 425 been identified as approximately 3 CFU [48] . Future studies should therefore use a murine model squares. An increase in absorbance in correlation to an increase in lipopeptide was indicative of 650 protein binding to lipopeptide. 
